Patents Represented by Attorney Thomas E. LaGrandeur
  • Patent number: 7022674
    Abstract: The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in glycerin, and a strong linear correlation between the level of reactive aldehydes in glycerin and chemical stability of compositions comprising a polypeptide and glycerin is demonstrated. The invention includes aqueous compositions comprising a polypeptide and glycerin having improved chemical stability compared to compositions previously known.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: April 4, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Alby David Sharknas, Alex Mark Prokai, Joseph Vincent Rinella
  • Patent number: 6841371
    Abstract: Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hyper coagulable states, thrombotic disorders and disease states predisposing to thrombosis.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: January 11, 2005
    Assignee: Eli Lilly and Company
    Inventors: Bruce Edward Gerlitz, Bryan Edward Jones
  • Patent number: 6767539
    Abstract: The present invention provides a method of treatment of viral hemorrhagic fever with protein C. The claimed invention provides a needed therapy for a serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: July 27, 2004
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan